These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3478198)

  • 1. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
    Lambertenghi-Deliliers G; Maiolo AT; Annaloro C; Cortelezzi A; Pogliani E; Ganzina F; Polli EE
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1041-5. PubMed ID: 3478198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin in refractory acute leukemia.
    Fülle HH; Hellriegel KP
    Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
    Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
    Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
    Falkson G; Coccia-Portugal MA; Vorobiof DA; Terblanche AP; Dreyer R
    Am J Clin Oncol; 1986 Aug; 9(4):311-4. PubMed ID: 3463190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
    Carella AM; Martinengo M; Santini G; Gaozza E; Damasio E; Giordano D; Nati S; Congiu A; Cerri R; Risso M
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1673-8. PubMed ID: 3480803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.
    Garewal H; Durie BG; Greenberg B
    Oncology; 1987; 44(6):333-5. PubMed ID: 3684173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
    Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
    Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
    Leone G; Pagano L; Marra R; Di Pietro N; Storti S; Sica S; D'Onofrio G; Ganzina F
    Haematologica; 1989; 74(1):57-61. PubMed ID: 2498185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.
    Weiss MA; Drullinsky P; Maslak P; Scheinberg D; Golde DW
    Leukemia; 1998 Jun; 12(6):865-8. PubMed ID: 9639412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
    Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Cerri R; Risso M; Damasio E; Rossi E
    Cancer; 1985 Apr; 55(7):1452-4. PubMed ID: 3856461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Bernstein ML; Abshire TC; Pollock BH; Devine S; Toledano S; Steuber CP; Bowman WP; Buchanan GR
    J Pediatr Hematol Oncol; 1997; 19(1):68-72. PubMed ID: 9065722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia.
    Lambertenghi-Deliliers G; Pogliani E; Maiolo AT; Pacciarini MA; Polli EE
    Tumori; 1983 Dec; 69(6):515-9. PubMed ID: 6582678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.